Our top pick for
Zai Lab Limited is a biotechnology business based in the US. Zai Lab shares (ZLAB) are listed on the NASDAQ and all prices are listed in US Dollars. Zai Lab employs 859 staff and has a trailing 12-month revenue of around USD$28.8 million.
|52-week range||USD$43.06 - USD$193.54|
|50-day moving average||USD$168.2924|
|200-day moving average||USD$112.1543|
|Wall St. target price||USD$155.52|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.116|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$28.8 million|
|Gross profit TTM||USD$9.2 million|
|Return on assets TTM||-31.12%|
|Return on equity TTM||-55.99%|
|Market capitalisation||USD$14.3 billion|
TTM: trailing 12 months
There are currently 1.6 million Zai Lab shares held short by investors – that's known as Zai Lab's "short interest". This figure is 20% down from 2.0 million last month.
There are a few different ways that this level of interest in shorting Zai Lab shares can be evaluated.
Zai Lab's "short interest ratio" (SIR) is the quantity of Zai Lab shares currently shorted divided by the average quantity of Zai Lab shares traded daily (recently around 411448.0620155). Zai Lab's SIR currently stands at 3.87. In other words for every 100,000 Zai Lab shares traded daily on the market, roughly 3870 shares are currently held short.
However Zai Lab's short interest can also be evaluated against the total number of Zai Lab shares, or, against the total number of tradable Zai Lab shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zai Lab's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Zai Lab shares in existence, roughly 20 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Zai Lab shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zai Lab.
Find out more about how you can short Zai Lab stock.
We're not expecting Zai Lab to pay a dividend over the next 12 months.
Over the last 12 months, Zai Lab's shares have ranged in value from as little as $43.06 up to $193.54. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zai Lab's is 1.1606. This would suggest that Zai Lab's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. The company offers Niraparib, an oral small molecule poly ADP ribose polymerase 1/2 inhibitor for the treatment of multiple solid tumors, including ovarian and other types of lung cancer; and Optune, a cancer therapy for the treatment of glioblastoma multiforme. It also develops Ripretinib, a switch control inhibitor for the treatment of KIT and/or PDGFRa-driven cancers, including gastrointestinal stromal tumors, systemic mastocytosis, and other cancers; REGN1979 for the treatment of diffuse large B-cell lymphoma and follicular lymphoma; Margetuximab an immune-optimized anti-HER2 monoclonal antibody for the treatment of breast and gastric cancers; and INCMGA0012, an investigational monoclonal antibody for the treatment of MSI-high endometrial cancer. In addition, the company develops Bemarituzumab, a humanized monoclonal antibody for the treatment of gastric and gastroesophageal cancers; Omadacycline, an antibiotic to treat acute bacterial skin and skin structure, and community-acquired bacterial pneumonia infections; and Durlobactam for the treatment of acinetobacter baumannii bacterial infections. Zai Lab Limited has license and collaboration agreements with the TESARO Inc.; Paratek Bermuda, Ltd.; Five Prime Therapeutics, Inc.; Entasis Therapeutics Holdings, Inc.; Crescendo Biologics Ltd.; Novocure Limited; MacroGenics Inc.; Deciphera Pharmaceuticals, LLC; and Incyte Corporation. The company was founded in 2013 and is headquartered in Shanghai, China.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.